US FDA Biosimilars Staff Faces More Transition As Sue Lim Departs After Christl

Sue Lim, who serves as director of scientific review staff of the US FDA's Therapeutic Biologics and Biosimilars Staff, will be leaving the agency at the end of February to start an independent consulting firm.